CEB-01

CEB-01 is a biodegradable polymer membrane that surgeons place at the tumor bed after cutting out abdominal cancers. It slowly releases SN-38 (the active form of irinotecan) directly into tissue that might still harbor cancer cells. CEBIOTEX, a small Spanish biotech, completed a Phase 1 dose-finding study in retroperitoneal sarcoma (a cancer arising in the abdominal cavity behind the intestines, n=21, published in Annals of Surgical Oncology in 2026) [1] and is running two Phase 2 trials: pediatric resectable abdominal tumors (NCT06986811, n=60) [2] and locally resectable pancreatic cancer (NCT06538857, n=39) [3]. The pitch: deliver harsh chemo right where residual disease sits and skip the systemic toxicity that limits IV irinotecan. The bet matters because local recurrence is a meaningful first failure event after pancreatic resection (40-60% local-regional recurrence as first failure in older randomized trials, 12-20% local-only in modern surgical series; systemic spread dominates overall) [6] and is the dominant failure mode in retroperitoneal sarcoma. There is no approved drug specifically aimed at the post-surgical bed niche in these cancers.

CEB-01 is investigational and has no approvals anywhere. The Phase 1 in retroperitoneal sarcoma (NCT04619056) completed with 21 patients, with the dose-finding paper published in Annals of Surgical Oncology in 2026 [1][4]. Two Phase 2 trials are recruiting: NCT06986811 in pediatric resectable abdominal tumors with a target of 60 patients, and NCT06538857 in locally resectable pancreatic cancer with a target of 39 patients [2][3]. Combined Phase 2 enrollment across the program is 99 patients. Both Phase 2 protocols list frequency of adverse events as the primary endpoint, not efficacy. These are expanded dose-confirmation and feasibility studies, not registrational designs. No FDA breakthrough therapy, fast track, orphan, or RMAT (Regenerative Medicine Advanced Therapy, an FDA fast-track category for cell/tissue products) designation has been disclosed for the program. More importantly for an EU-sponsored asset, no public EMA orphan designation or PRIME (PRIority MEdicines, EMA's accelerated assessment pathway) designation has been disclosed either. Given the Spanish sponsor and European trial geography, the realistic first regulatory submission is to EMA, not FDA. Under EU rules the implant is a drug-device combination subject to the Medical Device Regulation (MDR) in parallel with the centralized drug authorization. CEBIOTEX has not publicly stated an expected readout date. Given Phase 2 recruitment started in 2024 with modest enrollment targets, top-line safety data could surface around 2027. Anything beyond that, including a randomized Phase 3 or BLA (Biologics License Application, the FDA filing for biologic-type products) / MAA (Marketing Authorisation Application, the EMA equivalent), depends on whether these single-arm trials throw off a recurrence-rate signal worth chasing and whether CEBIOTEX can attract a partner with the capital to fund registration.

Irinotecan is an old chemo drug. The body converts about 5% of an IV dose into SN-38, which is the molecule that actually kills cancer cells, and SN-38 is roughly 1000-fold more potent than irinotecan itself. The catch: SN-38 is too toxic to administer intravenously. CEB-01 sidesteps this by embedding SN-38 in a biodegradable polymer membrane (PLGA, the same material used in dissolvable sutures) that surgeons drape over the tumor bed after resection. The Phase 1 program established sustained SN-38 release over approximately 28 days before the membrane fully degrades [1]. SN-38 works by blocking topoisomerase I (TOP1), an enzyme cancer cells need to unwind DNA before they can copy it. Block TOP1 in the middle of cleaving DNA and you trap the DNA in a broken state; when the cell tries to divide, it dies. The TOP1 mechanism is well-validated - irinotecan and topotecan have been FDA-approved since 1996, and irinotecan is standard care in colorectal and pancreatic cancer. The biological rationale for local delivery is solid. After surgery, microscopic residual disease in the tumor bed drives local recurrence. Systemic chemo reaches these cells poorly because the surgical bed has disrupted vasculature. A local depot bypasses that limitation. The conceptual analog is Gliadel (carmustine-loaded wafer, FDA-approved 1996 for glioblastoma): same idea of putting chemo directly where the surgeon cut, different polymer, different drug, different tumor.

NCT06986811 is a Phase 2, single-arm, open-label study in children with locally resectable abdominal solid tumors. Target enrollment is 60 patients. Primary endpoint is the frequency of adverse events [2]. NCT06538857 follows the same template in adults with locally resectable pancreatic cancer at n=39 [3]. Neither trial has a comparator arm. Patients are post-resection, with the membrane placed at the surgical bed. The Phase 1 (NCT04619056) findings frame what these Phase 2s are testing [1][4]. The Phase 1 enrolled patients with recurrent or locally advanced (unresectable) retroperitoneal sarcoma - a different population than the Phase 2 trials, which target resectable patients undergoing curative-intent surgery. The Phase 1 established a recommended Phase 2 dose (RP2D), confirmed approximately 28-day sustained SN-38 release from the membrane, and reported preliminary local-control signals that were considered sufficient to justify Phase 2 expansion. Note the population shift: a chemo-loaded implant placed in a pre-treated unresectable tumor bed is a different mechanical and biological setting than placement at a fresh anastomosis after curative resection. Phase 1 safety in the recurrent/advanced setting may not directly predict surgical-complication rates in the resectable Phase 2 populations. The good: pediatric inclusion is unusual and useful. Most chemotherapeutics get tested in adults for years before pediatric studies start. Both trials enroll patients where local recurrence is the dominant failure mode, so even a noisy efficacy signal would be informative if recurrence rates beat historical controls. The concerning: single-arm safety-focused designs cannot demonstrate efficacy. The primary endpoint is AE frequency, meaning these studies are powered to find safety signals, not to register the drug. CEBIOTEX will need randomized data versus surgery alone or surgery plus standard adjuvant chemo for any regulatory submission. These Phase 2 readouts are dose-and-feasibility steps. Enrollment pace at a small number of European centers will determine whether even these intermediate readouts arrive on the projected timeline. The pediatric trial's mixed tumor types (Wilms, neuroblastoma, sarcoma subtypes) also limit per-indication interpretation.

Our model gives this drug a 4% chance of eventually being approved. That starts from the historical approval rate for Phase 2 drugs in this area - about 13% - then adjusts based on ten facts about the trial and sponsor. The estimate gets a small boost from a non-randomized trial design and an above-average number of secondary endpoints, but is pulled down by the sponsor's thin or weak approval record and weak or limited earlier-phase results. Everything else falls close to average for this stage, so those factors leave the estimate roughly where the base rate started.

Efficacy risk dominates. Both ongoing Phase 2 trials are single-arm and safety-primary. Without a comparator, strong-looking local recurrence rates can be explained by patient selection rather than by drug effect. The pediatric trial spans heterogeneous tumor types (Wilms, neuroblastoma, sarcoma subsets), so a real recurrence signal in one subset could be diluted across the cohort. Safety risk has two components. SN-38 administered locally is still SN-38: in the Phase 1 retroperitoneal sarcoma study, doses were tolerable but gastrointestinal and wound-healing concerns were flagged [1]. Placing a chemotherapy depot at a fresh pancreatic anastomosis (the surgical reconnection of the pancreatic duct after the Whipple procedure; NCT06538857) is mechanically aggressive. Pancreatic fistula, anastomotic leak, and delayed wound healing are realistic worries. The pediatric trial inherits these issues with added scrutiny over long-term developmental effects of local chemo in children. The shift from the Phase 1 population (recurrent/advanced, no fresh anastomosis) to the Phase 2 populations (post-curative-resection, fresh surgical reconnections) means Phase 1 safety does not directly translate. Execution risk is high. CEBIOTEX is a small private Spanish company with no public partnership announced and no public disclosure of capital on hand sufficient to fund Phase 3. Funding a Phase 3 randomized trial (plausibly $50M or more) requires either a strategic partner or a substantial raise. Neither has surfaced. Regulatory strategy is also uncertain: with European trial sites and a Spanish sponsor, EMA is the more likely first filing path, but no EMA orphan or PRIME designation has been disclosed. Commercial risk: the addressable market is constrained by surgical eligibility. The drug requires an open procedure rather than a laparoscopic one and depends on the surgeon being willing and trained to place the implant. Reimbursement for drug-device combination products is structurally messy in both US (FDA-CDRH/CDER combination product rules) and EU (parallel EMA and MDR pathways) markets. The addressable surgical universe is also small: roughly 5,000 Whipple procedures per year across the US and EU for pancreatic cancer, plus a few thousand retroperitoneal sarcoma resections - a low-volume specialty-surgery market. The Gliadel commercial trajectory, where a clinically reasonable product peaked at ~$25M in annual US sales [7], is the cautionary precedent.

Watch, do not act. The Phase 1 retroperitoneal sarcoma paper is the first real data point and worth reading carefully. Any meaningful reduction in local recurrence in a tumor with limited adjuvant options would be a genuine signal [1][4]. The two Phase 2 trials are safety-primary, so the next data milestone is whether the membrane causes unacceptable surgical complications, not whether it works. Real efficacy data with a control arm is still 2-3 years out. Check back in late 2026 for any extended Phase 1 follow-up on long-term recurrence in the retroperitoneal sarcoma cohort. Check back in 2027 for top-line safety from either Phase 2 [2][3]. Signals that would change the assessment: a CEBIOTEX partnership announcement with a larger oncology developer, disclosure of EMA orphan or PRIME designation, a meaningful capital raise sufficient to fund a randomized Phase 3, or compelling recurrence-rate data presented at a major surgical oncology meeting with historical-control comparison. CEBIOTEX is small, the science is sensible, the precedent (Gliadel) is mixed, and the addressable surgical market is small even in a success case. CEB-01 fits a niche, adjuvant local chemo for resectable abdominal solid tumors, that essentially nobody else is working on right now. That is both the opportunity and the risk. If it works, CEBIOTEX or its acquirer owns a defensible category. If it does not, the company likely lacks the resources to pivot.